Effect of Angiotensin-converting enzyme inhibitors and Angiotensin receptor antagonists in atherosclerosis prevention.

Current Cardiology Reports
Maria M Patarroyo Aponte, Gary S Francis

Abstract

Atherosclerosis is a highly complex biological process that has become the scourge of modern civilization. Endothelial dysfunction is the first step in the development of atherosclerosis. The renin-angiotensin-aldosterone system (RAAS) plays an important role in the development of endothelial dysfunction and atherosclerosis. Several studies have shown that in vitro blockade of the RAAS is associated with improvement in markers of endothelial dysfunction and inflammation. Many clinical trials have demonstrated a clear benefit of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) manifested by a reduction of cardiovascular events. These findings suggest that ACEIs and ARBs can play an important role in prevention of atherosclerosis and in the delay of its progression. In this review we focus on the importance of RAAS blockade to prevent or delay progression of atherosclerosis and its impact on reduction of cardiovascular events.

References

May 15, 1998·Journal of the American College of Cardiology·M J MullenJ E Deanfield
Apr 24, 1999·The American Journal of Cardiology·U IkedaK Shimada
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
May 31, 2001·Clinical and Experimental Pharmacology & Physiology·B V MühlenL Lind
Nov 6, 2001·The American Journal of Cardiology·V J DzauUNKNOWN Working Group on Tissue Angiotensin-converting enzyme, International Society of Cardiovascular Pharmacotherapy
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Nov 11, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Dilek YavuzSema Akalin
Nov 12, 2003·The New England Journal of Medicine·Marc A PfefferUNKNOWN Valsartan in Acute Myocardial Infarction Trial Investigators
Feb 12, 2004·Kidney International·Aud HøieggenUNKNOWN LIFE Study Group
Aug 18, 2004·Circulation·Danilo FliserUNKNOWN EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Sep 24, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Saiko WatanabeShinichiro Ueda
Dec 13, 2005·Current Opinion in Nephrology and Hypertension·Ingrid FlemingRudi Busse
Dec 15, 2005·The Journal of Clinical Endocrinology and Metabolism·Thomas S HermannChristian Torp-Pedersen
Dec 5, 2006·Cardiovascular Research·Claudio CeconiUNKNOWN PERTINENT Investigators and the Statistical Committee

❮ Previous
Next ❯

Citations

Mar 4, 2014·Vascular Pharmacology·XiaoOu MaoDavid A Greenberg
Aug 21, 2013·International Journal of Cardiology·Aaron L SverdlovJohn D Horowitz
Mar 20, 2013·Korean Circulation Journal·Seung-Jun Lee, Sung-Ha Park
Feb 6, 2017·Circulation Research·Xiaoming HuFrank M Faraci
Mar 13, 2019·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Osman KayapinarAdnan Kaya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.